Leigh Vosseller: Great. Yes. So with the first question, Jason, there were two dynamics in the first quarter. We had benefit from people who had been waiting for Mobi from last year. And so that really helped the quarter. But we also know of and saw that where people were waiting to buy their Mobi in the second quarter from G7. So it’s a little bit of both in the first quarter. And so we – it’s going to be – that’s why at this point, we’re not talking about real trends because we’re not going to see a normalized quarter probably for another quarter or two until we get fully launched with the G7 integration. But I would say if you take it away from not just the numbers, but just the level of enthusiasm and excitement, it’s been really buzzing around the company, people calling in.
There’s a lot of activity, everyone’s interested in the product. And so we’ll be excited to see how that settles out into a normalized pattern. When it comes to the installed base, you’re right, we didn’t comment to it specifically this quarter. It’s really a simple 4-year rolling pump shipment calculation, which for end of first quarter would have put us at about 460,000 customers worldwide. And it was – it puts us at 315,000 in the U.S. and about 145,000 outside the U.S.
Jayson Bedford: Thank you.
Operator: Thank you. One moment for our next question. And our next question comes from the line of Jeff Johnson from Baird. Your question, please.
Jeff Johnson: Thanks. Good evening, guys. Leigh, maybe just a couple of cleanups or clarifying questions at this point. On the pricing side, would we expect in the U.S. pricing for both Mobi and t:slim to be at these elevated levels, they both at similar levels going forward? And was that price increase contemplated when you first gave guidance for 2024 last quarter? Thanks.
Leigh Vosseller: Yes. So yes to both questions, pricing is the same for t:slim and Mobi. And the pricing benefit that we saw this quarter is really a lot of work across all of last year from our market access team negotiating price improvements with various payers and going in and talking about Control-IQ, the value proposition, and we’re really just seeing it all come to fruition this quarter. And so that – it’s roughly the 4,000 mark for pumps you can assume for the rest of the year, and it’s very much in line with what we used in our guidance expectations.
Jeff Johnson: Okay. And then I was hoping you could maybe help me triangulate pump number in the U.S. a little bit better. So you’ve said two things. You’ve said that new starts a little bit higher than renewals. And then you’ve said that the split was a little bit higher to new starts as well. And not to parse words, but if I felt like a 55-45 split on your 15,000 U.S. number, I get like a 1,500, obviously, that’s the math, but a 1,500-patient difference between new starts and renewals. If I take your word that it’s just a little bit higher in patient numbers in new starts versus renewals, like maybe there’s a 500 split. Can you help us titrate? I mean, was the split between new users and renewals, a few hundred patients, 1,000 patients, just anything so we can keep our model kind of going as we built out on these new starts versus renewals over the years? I would appreciate anything you can give there?
Leigh Vosseller: Yes. I mean really, it’s just slightly more than half when you think about it from a new perspective. And so it was a good outcome from what we had been seeing last year and Mobi really helped drive that. And in our other new sensor integrations were also beneficial to it. And we expect over time that Mobi and the new products will continue to drive more in that new population. And keep in mind, renewal stepped up pretty significantly double digits this quarter like we’ve been seeing last year because of the growing opportunity base there. But I would say just roughly knew it’s just a little more than cash.
Jeff Johnson: Thank you.
Operator: Thank you. One moment for our next question. And our next question comes from the line of Josh Jennings from TD Cowen. Your question, please.
Josh Jennings: Hi, good evening, thanks. I was hoping to just follow up on Matt’s question on the type 2 study and that indication. I think, John, you’ve mentioned in previous discussions about potentially if all goes well, being able to commercialize next year and that type 2 insulin intensive spot. I was hoping you could just walk us through, again, assuming all goes well with the data and we get into next year, just from the data and is there submission, then there’s coverage? And any just timing that we should be thinking about in terms of potential to commercialize in that indication next year? And then just Mobi coming on board for that indication as well, what are the steps that are acquired? Thanks for taking the questions.
John Sheridan: Sure. I think that the timing is – we said we’re about a month away from complete enrollment. And then we have approximately – it’s approximately a 3-month study. So that takes us – and then we’ve got to prepare the clinical report and we’ve got to get it into the FDA. The FDA has seen this product now multiple times. And I think that the results are actually fantastic with the type 2 community. So I really feel that it’s going to be a 2025 product. It’s just difficult to predict when. I think that the commercial team is ready. We’re getting all of the strategy set up so that in terms of just the sales messaging, et cetera. But from a reimbursement point of view, it’s already being reimbursed, and I don’t think that’s going to be a challenge for us.
I think that we will be reimbursed as soon as it’s available. And once the Control-IQ algorithm is approved for type 2, you can use it on any interoperable pump. And so both t:slim and Mobi are interoperable pumps. So we will introduce it on both products simultaneously.
Josh Jennings: Great. Thanks a lot, John.
John Sheridan: Yeah.
Operator: Thank you. One moment for our next question. And our next question comes from the line of Travis Steed from BoA. Your question, please.
Travis Steed: Hey. Thanks for taking the questions. I’ll ask both upfront. Just a quick clarification on the full year guidance. I think before you’d said new growth would be flat to slightly down this year. Just curious if you’re still expecting new patients is going to be flat to slightly down at this point, given what you’re seeing with Mobi. And then on the – in the U.S., it looks like the ASP at least in our model, consumables were a little lower than they had been. I don’t know if that’s a trade-off higher, pump ASP. Just curious if there’s something going on the consumer side there. Just any color there would be helpful. Thanks a lot.
Leigh Vosseller: Sure. From a guidance perspective, I still thinking about along the lines of new starts being flat to slightly down, I would say, barring the outperformance we had in the first quarter because that’s where that came from. But the way the guidance was structured initially, it’s still with those thoughts in mind for the remainder of the year. And until we see some sort of trend that we can build models off of, we won’t be informing anything new to guidance for the new products. So probably, at least not for another quarter or two. When it comes to your question on supply, nothing unusual from the U.S. perspective on the supply side. Supply sales grew roughly in line with the installed base growth. We continuously monitor activity in the installed base in terms of who’s using the product if we see any different signs of attrition, and we haven’t seen any changes in that regard. So I’d probably just noise in your numbers.
Travis Steed: Okay. Great. I might have had the wrong number and something. Thanks a lot.
Leigh Vosseller: That’s, okay. Thanks, Travis.
John Sheridan: Thanks, Travis.
Operator: Thank you. [Operator Instructions] One moment for our next question. And our next question comes from the line of Michael Polark from Wolfe Research. Your question, please.
Michael Polark: Good afternoon. Thank you. I just have one on this potential shift into the pharmacy channel. Leigh, I heard you say it’s no longer a question of if, but when. I’m interested philosophically on how you think about managing this because as I look at it, it’s a potential for a license to subscription conversion, taking a big upfront revenue recognized amount and spreading it over some period of time. So how do you think about managing that? And when you say it’s a question of when, is that – is that suggesting you will have a lot of room to manage this if this is a desirable channel? Or is the one more just pay. Now we have to get in front of payers and get contracts up and running. Any color on this would be great. Thank you so much.
